Loading…
Loading…
how do you square your expectations in terms of peak with an increasingly crowded development landscape inclusive of other agents like IL-22s
I wanted to get your thoughts on the competitive landscape, particularly with the rollout of code
can you talk about the sizing of that opportunity given the dirt that's systemic options
Can you talk to uptake of the [ VYALEV ] and specifically what you're seeing regarding competitive dynamics
Can you talk about the extent to which the underlying IgG related disease population is larger than what literature has suggested historically and what that means for the underlying opportunity.
Can you talk to the extent to which there's been pent-up demand here? Give us your refreshed views on the sales opportunity here?
what is your appetite for significant consequential M&A regarding rare diseases? And what is your appetite in general for continuing to build out that broad therapeutic vertical?
what's it going to take to see an inflection here? Or maybe put differently, do you think there has to be some externality like the availability of a subcu form to get the product really moving again?
KRYSTEXXA, how are you thinking about the growth runway there and the potential for biosimilar down the road? And then also how you're thinking about the competitive landscape for TEPEZZA?
Wondering broadly how wide of a development that you are going to cast regarding the molecule
how are you thinking about where SYFOVRE is going to fit in this evolving landscape
how are you thinking about keeping the asset now that more well-resourced well-capitalized partner now controls the other 50%
how are you thinking about dapirolizumab and litifilimab in the context of a more crowded landscape that potentially could include oral agents
I wanted to get a better sense from you on what you'd like to see from CDR Sum of Boxes
A number of companies developing their own m one, m fours, and in some cases without a peripherally acting anticholinergic
how big of a priority is it to add a late-stage or commercial-ready psychiatry-focused asset or assets where you could leverage the commercial infrastructure
how you're thinking about potential or key barriers to adoption thus far
how are you thinking about your ability to drive a steady cadence of new starts with the additional competition
I wanted to ask about the hormonal patch business with the acceleration following the removal of the box warnings.
I want to get a better sense of what Viatris is aspiring to be regarding the innovative business in the United States
can you just remind us where you are in your exclusivity runway or potential exclusivity runway for the meloxicam product
can you talk to how you see differentiation versus the other modalities that have come on the market
can you just remind us how you're thinking of your IP/exclusivity runway for that product
on meloxicam, can you just talk about the commercial infrastructure you're going to be putting in place here
looking beyond Indore, can you just talk about inspections at the other facilities that you've called out in the past
can you just talk about contribution from new products in developed markets this year, if you can quantify that
On Indore, can you talk about 2026 and the potential for impact to spill over into 2026. How should we think about that
taking on assets that are in mid to late stage development along the lines of Cenerimod and Selatogrel
on cenerimod and selatogrel, just given your comments on enrollment, can we assume that these are going to be [27] (ph) events in terms of the data
can you just talk about your level of confidence that this is something that is contained to Indore
what does Viatris want to be longer term? I mean, do you want to lean more into brands